The bowel refers to the lowermost portion of the gastrointestinal (GI) tract. Structural or biochemical abnormalities associated with the bowel can give rise to a variety of disorders, with common examples including ulcerative colitis and Crohn’s disease, collectively termed inflammatory bowel disease. In the case of ulcerative colitis, there is chronic inflammation of the colon and rectum. Meanwhile in Crohn’s disease, though inflammation may occur anywhere along the gut, it most frequently manifests in the ileum.
Featured Learning Zones
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Inflammatory Bowel Disease
Treatment options for inflammatory bowel disease (IBD) are evolving as knowledge of the condition is increasing. In the future, physicians may be able to offer therapy tailored to individual patients. This Learning Zone describes the background behind such advances.
Recurrent or persistent abdominal pain, diarrhoea, fatigue and loss of appetite are some of the symptoms most frequently reported by patients with bowel disorders. Treatment of bowel disorders can prove challenging; however alleviation of symptoms may be achieved through dietary alterations or pharmacological interventions.
To find out more about the diagnosis and treatment of some of the most common bowel disorders, visit our dedicated “Anti-integrins in IBD” and “Inflammatory bowel disease assessment tools” Learning Zones, with a disease overview available in our Inflammatory Bowel Disease Knowledge Centre.
Related news and insights
AbbVie has announced that Health Canada has approved Humira (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids and/or azathioprine or 6- mercaptopurine or who are intolerant to such therapies.
Eli Lilly and Company has announced that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase III induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC).
The guideline has been condensed into two papers,[...] the second describing current therapeutic management [treatment of active disease and maintenance of medically induced remission].
The goal of this consensus initiated by the European Crohn’s and Colitis Organisation [ECCO] and European Society of Colo-Proctology [ESCP] was to establish European consensus guidelines for the surgical treatment of Crohn’s disease [CD].